Back to top
more

Viking Therapeutics (VKTX)

(Delayed Data from NSDQ)

$34.03 USD

34.03
2,699,762

+0.05 (0.15%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $34.01 -0.02 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider

by Zacks Equity Research

Viking Therapeutics, Inc. (VKTX) closed at $67.10 in the latest trading session, marking a +0.55% move from the prior day.

Kinjel Shah headshot

NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise

by Kinjel Shah

Stocks of LLY, VKTX and GPCR, which make oral pills for obesity, rose on Wednesday in response to Novo Nordisk's positive data.

Zacks Equity Research

Novo Nordisk Stock Rises as Oral Obesity Pill Outshines Wegovy

by Zacks Equity Research

NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage study.

Zacks Equity Research

Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?

by Zacks Equity Research

The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Andrew Rocco headshot

Why you Should Buy the 200-day Dip in ARM, MSTR, VKTX

by Andrew Rocco

The 200-day moving average can provide some of the best long-term entry points. MicroStrategy, Coinbase, and Viking Therapeutics offer high reward-to-risk as they retreat to an important technical level.

Zacks Equity Research

Viking Therapeutics, Inc. (VKTX) Laps the Stock Market: Here's Why

by Zacks Equity Research

Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $54.78, signifying a +1.2% move from its prior day's close.

Zacks Equity Research

Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

by Zacks Equity Research

Viking Therapeutics, Inc. (VKTX) reachead $58.10 at the closing of the latest trading day, reflecting a -0.5% change compared to its last close.

Sundeep Ganoria headshot

Viking Surges 342% in the Past Year: How Should You Play the Stock?

by Sundeep Ganoria

VKTX stock continues to generate phenomenal returns, driven by encouraging development of its obesity and NASH drugs, which are nearing late-stage development.

Zacks Equity Research

Bioventus and Pool have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Bioventus and Pool have been highlighted as Zacks Bull and Bear of the Day.

Zacks Equity Research

Eli Lilly Launches Discounted Versions of Obesity Drug Zepbound

by Zacks Equity Research

LLY's single-dose vials are priced at least 50% lower than the list price of all other GLP-1 medicines for obesity.

Zacks Equity Research

Why Viking Therapeutics Stock Price Moved Down 6% on Tuesday

by Zacks Equity Research

VKTX's shares fell after rival Eli Lilly announced that it is launching cheaper versions of Zepbound to strengthen its presence in the obesity market.

Zacks Equity Research

Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Viking Therapeutics (VKTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Sundeep Ganoria headshot

Viking (VKTX) Rises 25% in a Month: Should You Buy or Wait?

by Sundeep Ganoria

Despite having no marketed drugs, Viking's (VKTX) stock continues to experience robust price movement, driven by the company's encouraging progress with its pipeline.

Zacks Equity Research

Lilly (LLY) Up 3% on Obesity Drug Cutting Diabetes Risk

by Zacks Equity Research

Eli Lilly (LLY) reports data from a late-stage study that found that long-term treatment with Zepbound reduces the risk of progression to type 2 diabetes by 94%.

Zacks Equity Research

Zacks Investment Ideas feature highlights: Viking Therapeutics, McDonalds, Starbucks, Novo Nordisk and Eli Lilly

by Zacks Equity Research

Viking Therapeutics, McDonalds, Starbucks, Novo Nordisk and Eli Lilly have been highlighted in this Investment Ideas article.

Ahan Chakraborty headshot

Should You Invest in Novo Nordisk (NVO) Ahead of Q2 Earnings?

by Ahan Chakraborty

Novo Nordisk's (NVO) second-quarter revenues are expected to have been driven by its diabetes and obesity care product sales, especially Wegovy, Ozempic and Rybelsus.

Zacks Equity Research

Viking (VKTX) Q2 Earnings Beat, Stock Up on Pipeline Updates

by Zacks Equity Research

Viking (VKTX) gains 24% on better-than-expected second-quarter 2024 results, along with encouraging updates regarding its pipeline development plans.

Zacks Equity Research

The Zacks Analyst Blog Highlights Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences

by Zacks Equity Research

Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences are part of the Zacks Top Analyst Blog.

Ahan Chakraborty headshot

Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?

by Ahan Chakraborty

Let's look at five biotech and drug companies, AZN, ABBV, VKTX, SNY and BMY, slated to release their second-quarter 2024 results this week.

Zacks Equity Research

Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $50.90, marking a +1.6% move from the previous day.

Sundeep Ganoria headshot

Should Viking (VKTX) Stock be in Your Portfolio Pre-Q2 Earnings?

by Sundeep Ganoria

Devoid of marketed drugs, investors will focus on Viking Therapeutics' (VKTX) pipeline updates when it reports second-quarter results.

Zacks Equity Research

Why the Market Dipped But Viking Therapeutics, Inc. (VKTX) Gained Today

by Zacks Equity Research

Viking Therapeutics, Inc. (VKTX) reachead $50.12 at the closing of the latest trading day, reflecting a +0.56% change compared to its last close.

Sundeep Ganoria headshot

Novo Nordisk, Lilly Slide on Roche's Obesity Drug Study Data

by Sundeep Ganoria

Shares of obesity drugmakers Novo Nordisk (NVO) and Eli Lilly (LLY) lost market value on Wednesday after Roche (RHHBY) released positive early-stage data from a study on its obesity drug candidate.

Ahan Chakraborty headshot

Novo Nordisk (NVO) Soars 38% YTD: How Should You Play the Stock?

by Ahan Chakraborty

Novo Nordisk (NVO) is an excellent stock to retain as share prices continue to rise, driven by the stellar performance of GLP-1 drugs. New investors should look for stock price dips to make an entry.

Zacks Equity Research

Study Shows Lilly's (LLY) Obesity Drug More Effective Than NVO's

by Zacks Equity Research

Data from a new study, also published on the JAMA website, shows that patients taking Lilly's (LLY) obesity drug are likely to lose more weight than those taking Novo's drug.